Eradivir $10.25M Series A funding round
Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeutic
25 sept. 2024 10h00 HE | Purdue Research Foundation
WEST LAFAYETTE, Ind., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The...
Logo.png
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
25 sept. 2024 08h00 HE | Palisade Bio, Inc.
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA)...
kaida-biopharma-color copy(1).jpg
Kaida BioPharma Launches Social Media Channels
18 sept. 2024 10h00 HE | Kaida Biopharma
Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1...
Picture1.png
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
04 sept. 2024 09h25 HE | Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...
Logo.png
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
22 juil. 2024 08h00 HE | Hepion Pharmaceuticals, Inc.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
Logo.png
GRI Bio Announces Closing of $4.0 Million Public Offering
28 juin 2024 16h05 HE | GRI Bio, Inc.
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
logo.png
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
27 juin 2024 09h15 HE | GT Biopharma, Inc.
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550...
OPEN SANS HH STACKED_2.jpg
New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease
20 juin 2024 08h00 HE | Hemex Health
PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
ElmediX_blue_horizontal
ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
14 juin 2024 08h03 HE | Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer.  Earlier this year, scientists from Columbia University in New...